The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells

International Immunology

Volumn 14, Issue 12, 2002, Pages 1449-1457

  Abraham, Michal ^a   Shapiro, Sarah ^a   Lahat, Nitza ^a   Miller, Ariel ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Autoimmunity; Cytokines; Gelatinases; IL 4; Immunomodulation; Tumor necrosis factor

Indexed keywords

CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; CELL STRAIN U937; CHEMOTAXIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; MONOCYTE; PRIORITY JOURNAL; REVIEW;

CELL LINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-4; MATRIX METALLOPROTEINASES; MONOCYTES; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036919541     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/dxf108     Document Type: Review

References (60)

1. Goetzl, E. J., Banda, M. J. and Leppert, D. 1996. Matrix metalloproteinases in immunity. J. Immunol. 156:1.
2. Nagase, H. 1997. Activation mechanisms of matrix metalloproteinases. J Biol. Chem. 378:151.
3. Borden, P. and Heller, R. A. 1997. Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit. Rev. Eukar. Gene. Exp. 7:159.
4. Yong, V. W., Krekoski, C. A., Forsyth, P. A., Bell, R. and Edwards, D. R. 1998. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21:75.
5. Gijbels, K., Masure, S., Carton, H. and Opdenakker, G. 1992. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J. Neuroimmunol. 41:29.
6. Chandler, S., Miller, K. M., Clements, J. M., Lury, J., Corkill, D., Anthony, D. C. C., Adams, S. E. and Gearing, A. J. H. 1997. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72:155.
7. Kieseier, B. C., Kiefer, R., Clements, J. M., Miller, K., Wells, G. M., Schweitzer, T., Gearing, A. J. and Hartung, H. P. 1998. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121:159.
8. Mandler, R. N., Dencoff, J. D., Midani, F., Ford, C. C., Ahmed, W. and Rosenberg, G. A. 2001. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica. Brain 124:493.
9. Galboiz, Y., Shapiro, S., Lahat, N., Rawashdeh, H. and Miller, A. 2001. Matrix metalloproteinases (MMP) and their tissue inhibitors (TIMP) as markers of disease subtype and response to interferon-β therapy in relapsing and secondary progressive multiple sclerosis patients. Ann. Neurol. 443:451.
10. Gijbels, K., Galardy, R. E. and Steinman, L. 1994. Reversal of experimental autoimmune encephalomyelitis with hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94: 2177.
11. Matyszak, M. K. and Perry, V. H. 1996. Delayed-type hypersensitivity lesions in the central nervous system are prevented by inhibitors of matrix metalloproteinases. J. Neuroimmunol. 69:141.
12. Rosenberg, G. A., Dencoff, J. E., Correa, N., Reiners, M. and Ford, C. C. 1996. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46:1626.
13. Liedtke, W., Cannella, B., Mazzaccaro, R. J., Clements, J. M., Miller, K. M., Wucherpfennig, K. W., Gearing, A. J. H. and Raine, C. S. 1998. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann. Neurol. 44:35.
14. Lindberg, R. L., De Groot, C. J., Montagne, L., Freitag, P., van der Valk, P., Kappos, L. and Leppert, D. 2001 The expression profile of matrix metalloproteinases (MMP) and their inhibitors (TIMP) in lesions and normal appearing white matter of multiple sclerosis. Brain 124:1743.
15. Prat, A., Biernacki, K., Lavoie, J. F., Poirier, J., Duquette, P. and Antel, J. P. 2002 Migration of multiple sclerosis lymphocytes through brain endothelium. Arch. Neurol. 59:391.
16. Gomez, D. E., Alonso, D. F., Yoshiji, H. and Thorgeirsson, U. P. 1997. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J. Cell Biol. 74:111.
17. Lacraz, S,, Nicod, L., Galve de-Rochemonteix, B., Baumberger, C., Dayer, J. M. and Welgus, H. G. 1992. Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J. Clin. Invest. 90:382.
18. h2 cell membrane factors in association with IL-4 enhance matrix metalloproteinase-1 (MMP-1) while decreasing MMP-9 production by granulocyte-macrophage colony-stimulating factor-differentiated human monocytes. J. Immunol. 164:5952.
19. Saren, P., Welgus, H. G. and Kovanen, P. T. 1996. TNF-α and IL-1β selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol. 157:4159.
20. Zhang, Y., McCluskey, K., Fujii, K. and Wahl, L. M. 1998. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and independent mechanisms. J. Immunol. 161:3071.
21. Quiding-Jarbank, M., Smith, D. A. and Bancroft, G. J. 2001. Production of matrix metalloproteinases in response to mycobacterial infection. Infect. Immun. 69:5661.
22. Gerdes, N., Sukhova, G. K., Libby, P., Reynolds, R. S., Young, J. I. and Schonbeck, U. 2002. Expression of interleukin (IL)-18 and functional IL-18 receptor on vascular endothelial cells, smooth muscle cells and macrophages: implications for artherogenesis. J. Exp. Med. 195:245.
23. Dinarello, C. 1999. Interleukin-18. Methods 19:121.
24. Germann, T. and Rude, E. 1995. Interleukin-12. Int. Arch. Allergy Immunol. 108:103.
25. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
26. Swain, S. L. 2001. Interleukin 18: tipping the balance towards a T helper cell 1 Response. J. Exp. Med. 194:F11.
27. McInnes, I. B., Gracie, A., Leung B. P., Wei, X.-Q. and Leiw, F. Y. 2000. Interleukin 18: A pleiotropic participant in chronic inflammation. Immunol. Today 21:312.
28. + T cells via CD40 ligand. Proc. Natl Acad. Sci. USA 94:599.
29. Cawston, T. 1998. Matrix metalloproteinases and TIMP: properties and implications for rheumatic disease. Mol. Med. Today 3:130.
30. Van-Boxel-Dezaire, A. H., Hoff, S. C., van-Oosten, B. W., Verweij, C. L., Drager, A. M., Ader, H. J., van-Houwelingen, J. C., Barkhof, F., Polman, C. H. and Nagelkerken, L. 1999. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann. Neurol. 45:695.
31. Esfandiari, E., McInnes, I. B., Lindop, G., Huang, F. P., Field, M., Komai-Koma, M., Wei, X. and Liew, F. Y. 2001. A proinflammatory role for IL-18 in the development of spontaneous autoimmune disease. J. Immunol. 167:5338.
32. Moller, B., Kukoe-Zivojnov, N., Kessles, U., Rehart, S., Kaltwaser, J. P., Hoelzer, D., Halina, U. and Ottmann, O. G. 2001. Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis. Rheumatology 40:302.
33. + T cells via CD40-CD40 ligand interactions. J. Neuroimmunol. 125:134.
34. Keyszer, G,, Lambiri, I., Nagel, R., Keysser, C., Keysser, M., Gromnica-Ihle, E., Franz, J., Burmester, G. and Jung, K. 1999. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/ TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J. Rheumatol. 26:251.
35. Creange, A., Sharshar, T., Planchenault, T., Christov, C., Poron, F., Raphael, J. C. and Gherardi, R. K. 1999. Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barre syndrome. Neurology 53:1683.
36. Rajavashisth, T. B., Xu, X. P., Jovinge, S., Meisel, S., Xu, X. O., Chai, N. M., Fishbein, M. C., Kaul, S., Cercek, B., Sharifi, B. and Shan, P. K. 1999. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 99:3103.
37. Sitrin, R. G., Pan, P. M., Srikanth, S. and Todd, R. F. 1998. Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. J. Immunol. 161:1462.
38. Butler, G. S., Butler, M. J., Atkinson, S. J., Will, H., Tamura, T., Van Westrum, S. S., Crabbe, T., Clements, J., d'Ortho, M. P. and Murphy, G. 1998. The TIMP2 membrane type 1 metalloproteinase 'receptor' regulates the concentration and efficient activation of progelatinase A-a kinetic study. J. Biol. Chem. 273:871.
39. Dias, S., Boyd, R. and Balkwill, F. 1998. IL-12 regulates VEGF and MMP in a murine breast cancer model. Int. J. Cancer 78:361.
40. Constantinescu, C. S., Grygar, C., Kappos, L. and Leppert, D. 2001. Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells. Cytokine 13:244.
41. h2 cells and exerts its effect independently of IL-12. J. Immunol. 158:1541.
42. Stuyt, R. J., Netea, M. G., Kim, S. H., Novick, D., Rubinstein, M., Kullberg, B. J., Van der Meer, J. W. and Dinarello, C. A. 2001. Differential roles of interleukin-18 (IL-18) and IL 12 for induction of gamma interferon by staphylococcal cell wall components and superantigens. Infect. Immun. 69:5025
43. Galboiz, Y., Shapiro, S., Lahat, N. and Miller, A. 2000. Interferon-gamma and -beta modulation of matrix metalloproteinases and their tissue inhibitors expression in human monocytes. J. Neurol. 247:584 (Abstr.).
44. Shapiro, S. D., Campbell, E. J., Kobayashi, D. K. and Welgus, H. G. 1990. Immune modulation of metalloproteinase production in human macrophages. J. Clin. Invest. 86:1204.
45. Kumar, R., Pai, K. and Sundar, S. 2001. Reactive oxygen intermediates, nitrite, and interferon-gamma in Indian visceral leishmaniasis. Clin. Exp. Immunol. 124:262.
46. Strongin, A. Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A. and Goldberg, G. I. 1995. Mechanism of cell surface activation of 72-kDa type IV collagenase. J. Biol. Chem. 270:5331.
47. 2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J. Biol. Chem. 267:515.
48. Lacraz, S., Nicod, L. P., Chicheportiche, R., Welgus H. G. and Dayer, J. M. 1995. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 96:2304.
49. Mertz, P. M., DeWitt, D. L., Stetler-Stevenson, W. G. and Wahl, L. M. 1994. Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J. Biol. Chem. 269:21322.
50. Miller, A., Shapiro, S., Lahat, N. and Galboiz, Y. 2002. Matrix metalloproteinases and their inhibitors in brain injury and repair. In Abramsky O., Compston A., Said G. and Miller A., eds, Brain Disease: Therapeutic Strategies and Repair, p. 63. Martin Dunitz, London.
51. Yu, Q. and Stamenkovic, I. 1999. Cell surface-localized matrix metalloproteinase 9 proteolytically activates TGF-β and promotes tumor invasion. Genes Dev. 13:35.
52. Ito, A., Mukaiyama, A., Itoh, Y., Nagase, H., Thorgersen, I. B., Enghild, J. J., Sasaguri, Y. and Mori, Y. 1996. Degradation of interleukin 1β by matrix metalloproteinases. J. Biol. Chem. 271:14657.
53. Gearing, A. J. H, Beckett, M., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L. M. and Wolley, K. 1994. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 370:555.
54. Hooper, N. M., Karran, E. H. and Turner, J. 1997. Membrane protein secretases. Biochem. J. 321:265.
55. El-Shabrawi, Y. G., Christen, W. G., Foster, and S. C. 2000. Correlation of MMP-2 and -9 with proinflammatory cytokines IL-1β, IL-12 and the IL-1R antagonist in patients with chronic uveitis. Curr. Eye Res. 20:211.
56. h1 differentiation: an effect of the novel anti-inflammatory drug lisofylline. J. Immunol. 161:7015.
57. Wildbaum, G., Youssef, S., Grabie, N. and Karin, N. 1998. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J. Immunol. 161:6368.
58. Costa, G. L., Sandora, M. R., Nakajima, A., Nguyen, E. V., Taylor-Edwards, C., Slavin, A. J., Contag, C. H., Fathman, C. G. and Benson, J. M. 2001. Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit. J. Immunol. 167:2379.
59. h1 cytokine response. Immunity 10:127.
60. Rosenberg, G. A. 2001. Matrix metalloproteinases in multiple sclerosis: is it time for a treatment trial. Ann. Neurol. 50:431.